Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
1 Weight-Loss Stock That's Been a Hotter Buy Than Eli Lilly and Novo Nordisk This Year
10:00am, Thursday, 07'th Sep 2023
Shares of WW International have been soaring this year as a result of some promising drugs. Even companies that aren't involved in making the drugs have piggybacked on the hype.
Here are the 13 stocks Jim Cramer is watching, including Eli Lilly, McDonald's
09:50am, Thursday, 07'th Sep 2023
Here are some of the tickers on my radar for Thursday, Sept. 7, taken directly from my reporter's notebook.
3 Nasdaq Stocks to Sell in September Before They Crash & Burn
08:41am, Thursday, 07'th Sep 2023
Due to what could be an unsustainable rally for equities, you may be looking for Nasdaq stocks to sell now. We've had an incredible run this year, but there are some additional indiciations that our l
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
10:00am, Tuesday, 05'th Sep 2023
Eli Lilly is making big plays in three hot markets: Alzheimer's, pain, and obesity. It's already on the cusp of getting medicines approved in those spaces.
Here's 1 Stock That Could Join Apple and Amazon in the $1 Trillion Club That You Might Have Overlooked
09:12am, Tuesday, 05'th Sep 2023
Unlike the current five stocks with $1 trillion market caps, AI isn't a major factor for this contender. Instead, its fortunes rely largely on treating diabetes, obesity, and Alzheimer's disease.
Novo Nordisk Is Now Europe's Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.
05:06am, Tuesday, 05'th Sep 2023
The pharma company's Wegovy medication helps it overtake luxury goods maker LVMH, with a market value of around $420 billion.
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
07:01am, Friday, 01'st Sep 2023
Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen In
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
04:31am, Thursday, 31'st Aug 2023
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
7 Stocks Sitting At 52-Week Highs Right Now
07:17pm, Wednesday, 30'th Aug 2023
Propelled by strong earnings and upbeat guidance, the shares of several leading companies are now at their highest level in a year. And while some investors might be weary of stocks trading at 52-week
3 Dividend Stocks That Have Doubled Since 2020
01:48pm, Wednesday, 30'th Aug 2023
Bullishness in AI and weight-loss treatments have made Nvidia and Eli Lilly hot investments to own this year. Dick's Sporting Goods crashed in August after the company cut its guidance, but its gains
3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of
08:54am, Wednesday, 30'th Aug 2023
This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so far in 2023. Investors are probably worried about
The 3 Most Promising Pharma Stocks to Own Now
05:20am, Wednesday, 30'th Aug 2023
It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe dise
Global dividends hit record $568 billion, but pace of U.S. payouts slows for sixth straight quarter
01:57am, Wednesday, 30'th Aug 2023
Global dividends rose 4.9% to a record $568 billion in the second quarter, but the pace of growth in the U.S. slowed for the sixth consecutive quarter after some high- profile technology and financial
What the medicare decision means for pharma stocks
06:37pm, Tuesday, 29'th Aug 2023
Jared Holz, Mizuho, joins 'Fast Money' to talk the Biden Administration unveiling the first 10 drugs subject to medicare price negotiations and how pharma stocks are responding.
Better Pharma Growth Stock: Eli Lilly vs. Merck
10:15am, Tuesday, 29'th Aug 2023
Eli Lilly's Mounjaro is shaping up to be a long-term driver of earnings growth. The same is true for Merck's Keytruda, a medication for treating certain cancers.
